EyePoint expanded analysis of its LUGANO Phase 3 trial for DURAVYU in wet AMD, citing potential practice-changing data and renewed confidence just months before an anticipated FDA filing in 2027.
EyePoint expanded analysis of its LUGANO Phase 3 trial for DURAVYU in wet AMD, citing potential practice-changing data and renewed confidence just months before an anticipated FDA filing in 2027.